A Randomized, Double-Blind, Active Control, Multicenter, Dose-Finding Study of Lipegfilgrastim (XM22) in Breast Cancer Patients Receiving Myelosuppressive Therapy

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-014-3120-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search